Medical Glucose Monitoring Devices sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Glucose Monitoring Devices
1.1 - About Medical Glucose Monitoring Devices sector
Companies in this category design and manufacture devices and connected platforms to measure and track blood glucose for diabetes care. Medical Glucose Monitoring Devices span continuous and spot-check solutions that deliver accurate readings, actionable alerts, and longitudinal data to patients and clinicians. Vendors focus on clinical accuracy, connectivity, and workflow integration to enable real-time decision-making and programmatic population management.
Offerings commonly include continuous glucose monitoring sensors paired with patch transmitters, plus handheld glucometers for fingerstick testing with matching test strips and lancing devices. Vendors provide reader or receiver hardware and companion mobile apps that visualize trends, trigger hypoglycemia alerts, and support reporting to clinicians. Cloud dashboards aggregate longitudinal data, and integrations connect to insulin pumps, EHRs, and RPM portals via Bluetooth and APIs, backed by calibration and accuracy validation workflows.
Primary customers include hospitals and health systems, endocrinology and diabetes clinics, and remote patient monitoring program operators. These companies help buyers improve glycemic control, reduce hypoglycemia events and readmissions, increase patient adherence through real-time feedback, and streamline data capture in care pathways. Outcomes often include better population insights, stronger clinical quality metrics, and enhanced reimbursement performance for chronic disease programs.
2. Buyers in the Medical Glucose Monitoring Devices sector
2.1 Top strategic acquirers of Medical Glucose Monitoring Devices companies
Dexcom
- Description: Provider of continuous glucose monitoring solutions for diabetes management, Dexcom develops, manufactures and distributes a range of CGM systems worldwide, operating from its San Diego headquarters with additional manufacturing sites in the United States, Malaysia and Ireland.
- Key Products:
- Dexcom G7 Continuous Glucose Monitoring System: Wearable sensors deliver real-time glucose readings
- optional receiver or smart device displays data, with over $200 receiver savings and Medicare compatibility benefits
- Dexcom Pharmacy Savings Program: Coupon-based offer giving $210 off each 30-day sensor pack and transmitter, saving users over 50% on standard cash prices at retail and Amazon pharmacies
- Dexcom Patient Assistance Program: Income-based discount initiative requiring application and documentation, providing qualified U.S. residents reduced out-of-pocket costs for Dexcom CGM products
- Stelo Glucose Sensing Solution: Non-prescription, affordable device for type 2 diabetics not on insulin, providing real-time glucose readings and insights to support healthier lifestyle decisions.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Medical Glucose Monitoring Devices sector
M&A buyer group 1: Diabetes Devices
DarioHealth
- Type: N/A
- Employees: ●●●●●
- Description: Provider of data-driven digital health solutions for chronic condition management, offering an integrated platform of connected devices, mobile apps and analytics for diabetes, hypertension, weight, behavioral and musculoskeletal care, as well as employer and health-plan programs that improve outcomes and lower costs.
- Key Products:
- Diabetes Management Solution: Smartphone-connected digital therapeutic combining real-time glucose monitoring, personalized coaching, and evidence-based interventions to drive sustained behavior change and improved glycemic control
- Hypertension Management Solution: AI-driven program that pairs connected blood-pressure monitoring with adaptive software and coaching to help users track readings, receive feedback, and lower blood-pressure levels
- Cardiometabolic Suite for Employers: Multi-condition platform offered to employer populations, bundling diabetes, hypertension and related chronic-care programs to generate recurring outcomes-based revenue
- Multi-Condition Digital Therapeutics Platform: Core software infrastructure integrating life-science, behavioral-science and analytics capabilities to rapidly expand into additional chronic conditions and geographic markets.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Medical Glucose Monitoring Devices sector
3.1 - Buyout funds in the Medical Glucose Monitoring Devices sector
2.2 - Strategic buyer groups for Medical Glucose Monitoring Devices sector
4 - Top valuation comps for Medical Glucose Monitoring Devices companies
4.2 - Public trading comparable groups for Medical Glucose Monitoring Devices sector
Valuation benchmark group 1: Diabetes Care Device Companies
Medtronic
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of medical technology solutions including advanced devices and therapies for various medical conditions, focusing on cardiac care, neurological disorders, diabetes management, and surgical innovations to improve patient outcomes and enhance healthcare delivery.
- Key Products:
- Cardiac devices: Pacemakers and defibrillators for heart rhythm disorders
- Insulin pumps: Advanced systems for diabetes management
- Surgical innovations: Minimally invasive surgical tools and robotics
- Neurostimulation: Implants for pain management and neurological conditions
- Patient monitoring: Advanced monitoring systems for acute care.